Oral Biolife Assembles World-Class Scientific Advisory Board to Accelerate Development of Ambrilux Dental Gel

Dil Bar Irshad | August 1, 2025 | Featured Edition | Follow on Google News

 The Philadelphia-based biotech Company Shares Its Trusted Experts Supporting Innovation in Oral Health

Bethlehem, PA — (August 01, 2025) – Oral Biolife (OBL), a pioneering biotechnology company advancing innovative dental treatments for both humans and companion animals, finalized the formation of its Scientific Advisory Board (SAB). The board brings together nationally recognized leaders in periodontology, dental innovation, regenerative medicine, and veterinary medicine.

The SAB will provide strategic scientific guidance to support the development and clinical advancement of Ambrilux Dental Gel® – a novel, light-activated, gel-based device designed to promote bone regeneration and transform the management of periodontal disease in both humans and animals. 

Also Read: Rimere announces high-quality nanocarbon and graphene materials now available for commercial applications

Oral Biolife’s SAB includes:

• Dr. Ronaldo Santana, DMD, Chair of the Department of Periodontology and Oral Implantology at Temple University Kornberg School of Dentistry; expert in regenerative medicine and grant development      

• Dr. Ed Zuckerberg, DDS, FAGD, Digital dentistry pioneer and advocate for the oral-systemic health connection with a patient-centered approach to innovation.

• Dr. Pascal Kunz, MD, DMD, Entrepreneur and global leader in digital dental technologies, diagnostics, and guided robotic surgery, with dual expertise in medicine and dentistry.

• Dr. Lisa Stehno-Bittel, PhD, Founder and President of Likarda; authority in hydrogel-based cell therapies and therapeutic delivery.

• Dr. Shervin Molayem, DDS, Periodontist, implant surgeon, and researcher specialized in the intersection of oral health and systemic disease.

• Dr. Tanya Kameneva, DVM, Veterinary Key Opinion Leader (KOL) instrumental in shaping Oral Biolife’s companion animal strategy and preclinical development.

“This marks a major milestone for Oral Biolife,” said Dr. Stella Vnook, Founder & President of Oral Biolife. “We are honored to have the support of such a distinguished group of experts. Their insights and experience will be essential as we advance Ambrilux Dental Gel® toward clinical use and commercialization. Our SAB reflects Oral Biolife’s commitment to scientific rigor and real-world impact.”

About Oral Biolife Inc.
Oral Biolife is an innovative biotechnology company headquartered in Bethlehem, PA that utilizes the unique properties of biotechnology materials to develop groundbreaking, first-to-market products. Their lead asset, Ambrilux Dental Gel, via its unique ability to regenerate bone lost due to periodontal disease and represents a potential breakthrough for treating periodontal disease. 

For more information, please visit